Stocktoria
Simulations Plus, Inc. SLP
Simulations Plus, Inc. (SLP) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the safe zone. It pays a dividend yielding 1.30% (safety: no dividend). FY2025 revenue was $79.2M at a -81.7% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
Smart money · insiders, last 12 months
Open-market insider purchases minus sells (SEC Form 4) — real buying with their own money is a bullish “smart money” signal; grants and option exercises are excluded.
How it ranks in Services · percentile among 982 companies
Percentile vs other Services companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · safe zone
| Component | Value |
|---|---|
| Working capital / assets | 0.34 |
| Retained earnings / assets | -0.26 |
| EBIT / assets | -0.536 |
| Equity / liabilities | 17.491 |
Sector peers · similar-size Services companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| SLP | Simulations Plus, Inc. | 5/9 | 16.14 | — | +13.1% |
| PONY | Pony AI Inc. | 3/9 | 17.95 | — | +20% |
| CSPI | CSP INC /MA/ | 4/9 | 5.51 | — | +6.4% |
| CREX | CREATIVE REALITIES, INC. | 2/9 | -1.83 | — | +12.5% |
| IONQ | IonQ, Inc. | 3/9 | 2.63 | — | +201.9% |
| HCTI | Healthcare Triangle, Inc. | 2/9 | -7.03 | — | +18.8% |
| SLE | Super League Enterprise, Inc. | 4/9 | — | — | -29.9% |
About Simulations Plus, Inc.
Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. It operates through Software and Services segments. The company offers GastroPlus, which predicts absorption, biopharmaceutics, pharmacokinetics, and pharmacodynamics in humans and animals; and DDDPlus and MembranePlus simulation products. It also provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, OBESITYsym, and Thales products. In addition, the company offers Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Further, it provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Additionally, the company offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina.
FAQ
Is SLP financially healthy?
Simulations Plus, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the safe zone.
Does SLP pay a dividend, and is it safe?
Yes. Simulations Plus, Inc. pays a dividend yielding about 1.30% with a None payout ratio, rated “no dividend” for safety.
How profitable is SLP?
In FY2025, Simulations Plus, Inc. had a net margin of -81.7% and a return on equity of -51.9%.
Is SLP overvalued or undervalued?
Simulations Plus, Inc. trades at about 37.4× trailing earnings — below its 10-year norm (10-year range 30.4×–150.7×, median 72.3×). Stocktoria reports the data, not buy/sell advice.
What is the analyst price target for SLP?
The average Wall-Street price target for Simulations Plus, Inc. is $17.25, about 5.8% below the recent price, from 2 analysts (consensus: hold).
Is SLP a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Simulations Plus, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the safe zone, a dividend yield of 1.30%. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-08-31. Facts plus Stocktoria's own computed scores — not investment advice.